XML 70 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments and Fair Value Measurements (Tables)
 12 Months Ended
Dec. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:
December 30, 2022 (Successor)Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$36.6 $24.8 $11.8 $— 
Equity securities
25.5 25.5 — — 
$62.1 $50.3 $11.8 $— 
Liabilities:
Deferred compensation liabilities$26.0 $— $26.0 $— 
Contingent consideration liabilities7.3 — — 7.3 
$33.3 $— $26.0 $7.3 

December 31, 2021 (Predecessor)Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant Other Observable Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$38.7 $24.9 $13.8 $— 
Equity securities36.5 36.5 — — 
$75.2 $61.4 $13.8 $— 
Liabilities:
Deferred compensation liabilities (1)
$36.9 $— $36.9 $— 
Contingent consideration liabilities (2)
27.3 — — 27.3 
$64.2 $— $36.9 $27.3 
Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration The following table summarizes the fiscal 2022 activity for contingent consideration:
Balance as of December 31, 2021(Predecessor)$27.3 
Impact of the Plan on Predecessor contingent consideration liabilities(27.3)
Establishment of Terlivaz CVR6.8 
Balance as of June 16, 2022 (Successor)$6.8 
Balance as of June 17, 2022 (Successor)$6.8 
Fair value adjustments
0.5 
Balance as of December 30, 2022 (Successor)$7.3 
Schedule of Carrying Amount and Fair Value of Long-term Debt
SuccessorPredecessor
December 30, 2022December 31, 2021
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
10.00% first lien senior secured notes due April 2025$475.9 $425.9 $495.0 $523.7 
10.00% second lien senior secured notes due April 2025242.2 216.8 — — 
11.50% first lien senior secured notes due December 2028650.0 552.6 — — 
10.00% second lien senior secured notes due June 2029175.5 176.7 — — 
Revolving credit facility due February 2022— — 900.0 900.0 
5.75% senior notes due August 2022— — 610.3 324.1 
4.75% senior notes due April 2023— — 133.7 48.9 
5.625% senior notes due October 2023— — 514.7 279.1 
10.00% second lien senior secured notes due April 2025— — 322.9 312.7 
5.50% senior notes due April 2025— — 387.2 211.6 
Level 2:
2017 Replacement Term loan due September 20271,222.1 1,037.8 — — 
2018 Replacement Term loan due September 2027326.9 274.8 — — 
9.50% debentures due May 2022— — 10.4 7.7 
8.00% debentures due March 2023— — 4.4 3.2 
Term loan due September 2024— — 1,396.5 1,309.2 
Term loan due February 2025— — 370.7 347.7 
Total Debt$3,092.6 $2,684.6 $5,145.8 $4,267.9 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge related to the Medicaid lawsuit:
SuccessorPredecessor
Period from
June 17, 2022
 through
December 30, 2022		Period from
January 1, 2022
 through
June 16, 2022		Year Ended December 31, 2021Year Ended December 25, 2020
FFF Enterprises, Inc.26.1 %11.8 %*%*%
CuraScript, Inc.
*15.6 26.1 27.4 
* Net sales to this distributor were less than 10.0% of total net sales during the respective periods presented above.
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
SuccessorPredecessor

December 30,
2022

December 31,
2021
AmerisourceBergen Corporation23.3%30.0%
McKesson Corporation17.3 15.0
FFF Enterprises, Inc.16.2 *
CuraScript, Inc.*12.7
* Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge related to the Medicaid lawsuit:
SuccessorPredecessor
Period from
June 17, 2022
 through
December 30, 2022		Period from
January 1, 2022
 through
June 16, 2022		Year Ended December 31, 2021Year Ended December 25, 2020
Acthar Gel28.3 %25.4 %26.9 %27.9 %
INOmax16.7 19.0 20.3 20.9 
Therakos12.5 12.5 12.1 *
APAP10.7 11.0 **
Ofirmev***10.1